Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases

Expert Opinion on Drug Delivery

Volumn 8, Issue 5, 2011, Pages 605-621

  Lorberboum Galski, Haya ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

apoptosis; cancer; chimeric proteins; recombinant immunotoxins; single chain antibody; targeting

Indexed keywords

APOPTOSIS INDUCING FACTOR; BACTERIAL TOXIN; CASPASE; CASPASE ACTIVATED DEOXYRIBONUCLEASE; CHIMERIC PROTEIN; CYTOKINE; DENILEUKIN DIFTITOX; FAS LIGAND; GRANZYME A; GRANZYME B; GROWTH FACTOR; HORMONE; IMMUNOTOXIN; IMMUNOTOXIN LMB2; INTERLEUKIN 2 CASPASE 3; NEUTRALIZING ANTIBODY; PHOSPHOTRANSFERASE; PLANT TOXIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN BIK; PROTEIN TBID; RIBONUCLEASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

CELL DEATH; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; HUMAN; IMMUNOGENICITY; NONHUMAN; REVIEW; T CELL LYMPHOMA; TARGET CELL;

DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTOXINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECOMBINANT FUSION PROTEINS;

EID: 79955104910     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2011.566269     Document Type: Review

References (154)

1. Mathew M, Verma RS. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci 2009;100(8):1359-65
2. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256(5517):495-7
3. Skerra A, Pluckthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 1988;240(4855):1038-41
4. Toleikis L, Broders O, Dubel S. Cloning single-chain antibody fragments (scFv) from hybridoma cells. Methods Mol Med 2004;94:447-58
5. Chaudhary VK, Queen C, Junghans RP, et al. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 1989;339(6223):394-7 (Pubitemid 19144230)
6. Pastan I, Hassan R, FitzGerald DJ, et al. Immunotoxin treatment of cancer. Annu Rev Med 2007;58:221-37 (Pubitemid 46706511)
7. Brinkmann U, Pai LH, FitzGerald DJ, et al. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci USA 1991;88(19):8616-20 (Pubitemid 21915408)
8. Benhar I, Pastan I. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3. J Biol Chem 1995;270(40):23373-80
9. Zhu Z, Presta LG, Zapata G, et al. Remodeling domain interfaces to enhance heterodimer formation. Protein Sci 1997;6(4):781-8 (Pubitemid 27154804)
10. Pai-Scherf LH, Villa J, Pearson D, et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res 1999;5(9):2311-15 (Pubitemid 29437307)
11. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001;345(4):241-7 (Pubitemid 32695063)
12. Multani PS, ODay S, Nadler LM, et al. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkins lymphoma. Clin Cancer Res 1998;4(11):2599-604 (Pubitemid 28523485)
13. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000;18(8):1622-36 (Pubitemid 30220540)
14. Schnell R, Borchmann P, Staak JO, et al. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkins lymphoma. Ann Oncol 2003;14(5):729-36 (Pubitemid 36621773)
15. Kreitman RJ, Wilson WH, Robbins D, et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 1999;94(10):3340-8 (Pubitemid 29536127)
16. Amlot PL, Stone MJ, Cunningham D, et al. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 1993;82(9):2624-33 (Pubitemid 23318068)
17. Sausville EA, Headlee D, Stetler-Stevenson M, et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood 1995;85(12):3457-65
18. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005;23(27):6719-29 (Pubitemid 46190267)
19. Schnell R, Staak O, Borchmann P, et al. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkins and non-Hodgkins lymphoma. Clin Cancer Res 2002;8(6):1779-86 (Pubitemid 34633735)
20. Francisco JA, Schreiber GJ, Comereski CR, et al. In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40. Blood 1997;89(12):4493-500 (Pubitemid 27260259)
21. Peipp M, Kupers H, Saul D, et al. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res 2002;62(10):2848-55 (Pubitemid 34525770)
22. Pai LH, Wittes R, Setser A, et al. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med 1996;2(3):350-3 (Pubitemid 26082014)
23. Posey JA, Khazaeli MB, Bookman MA, et al. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 2002;8(10):3092-9 (Pubitemid 35155018)
24. Azemar M, Djahansouzi S, Jager E, et al. Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat 2003;82(3):155-64 (Pubitemid 37521971)
25. Goldberg MR, Heimbrook DC, Russo P, et al. Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clin Cancer Res 1995;1(1):57-61
26. Sampson JH, Akabani G, Archer GE, et al. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003;65(1):27-35 (Pubitemid 37441312)
27. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13(17):5144-9 (Pubitemid 47502082)
28. Foss FM, Bacha P, Osann KE, et al. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma 2001;1(4):298-302 (Pubitemid 32331686)
29. Dang NH, Hagemeister FB, Pro B, et al. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkins lymphoma. J Clin Oncol 2004;22(20):4095-102 (Pubitemid 41185178)
30. Frankel AE, Fleming DR, Hall PD, et al. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res 2003;9(10 Pt 1):3555-61 (Pubitemid 37169218)
31. Vallera DA, Seo SY, Panoskaltsis-Mortari A, et al. Targeting myeloid leukemia with a DT(390)-mIL-3 fusion immunotoxin: ex vivo and in vivo studies in mice. Protein Eng 1999;12(9):779-85 (Pubitemid 29472085)
32. Rand RW, Kreitman RJ, Patronas N, et al. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 2000;6(6):2157-65 (Pubitemid 30399180)
33. Weber FW, Floeth F, Asher A, et al. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 2003;88:93-103
34. Puri RK, Leland P, Obiri NI, et al. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 1996;87(10):4333-9 (Pubitemid 26155030)
35. Kawakami K, Kawakami M, Joshi BH, et al. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res 2001;61(16):6194-200 (Pubitemid 32762557)
36. Frankel AE, Powell BL, Hall PD, et al. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res 2002;8(5):1004-13 (Pubitemid 34517633)
37. Handa JT, Houston LL, Jaffe GJ. The antiproliferative effect of a transferrin-toxin on human retinal pigment epithelial cells and rabbit fibroblasts. Invest Ophthalmol Vis Sci 1993;34(12):3419-28 (Pubitemid 23346675)
38. Nechushtan A, Yarkoni S, Marianovsky I, et al. Adenocarcinoma cells are targeted by the new GnRH-PE66 chimeric toxin through specific gonadotropin-releasing hormone binding sites. J Biol Chem 1997;272(17):11597-603 (Pubitemid 27184172)
39. Ben-Yehudah A, Lorberboum-Galski H. Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteins. Expert Rev Anticancer Ther 2004;4(1):151-61 (Pubitemid 38208494)
40. Ben-Yehudah A, Prus D, Lorberboum-Galski H. I.V. Administration of L-GNRH-PE66 efficiently inhibits growth of colon adenocarcinoma xenografts in nude mice. Int J Cancer 2001;92(2):263-8 (Pubitemid 32225379)
41. Ben-Yehudah A, Yarkoni S, Nechushtan A, et al. Linker-based GnRH-PE chimeric proteins inhibit cancer growth in nude mice. Med Oncol 1999;16(1):38-45 (Pubitemid 29238380)
42. Ben-Yehudah A, Aqeilan R, Belostotsky R, et al. Utilizing chimeric proteins for exploring the cellular fate of endogenous proteins. Biochem Biophys Res Commun 2002;290(1):332-8 (Pubitemid 34694504)
43. Piascik P. FDA approves fusion protein for treatment of lymphoma. J Am Pharm Assoc 1999;39(4):571-2
44. Foss FM, Saleh MN, Krueger JG, et al. Diphtheria toxin fusion proteins. Curr Top Microbiol Immunol 1998;234:63-81 (Pubitemid 28238005)
45. Saleh MN, LeMaistre CF, Kuzel TM, et al. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 1998;39(1):63-73 (Pubitemid 28332309)
46. Lichtenstein M, Ben-Yehudah A, Belostotsky R, et al. Utilizing a GnRH-based chimeric protein for the detection of adenocarcinoma. Int J Oncol 2005;27(1):143-8
47. Eaveri R, Ben-Yehudah A, Lorberboum-Galski H. Surface antigens/receptors for targeted cancer treatment: the GnRH receptor/binding site for targeted adenocarcinoma therapy. Curr Cancer Drug Targets 2004;4(8):673-87 (Pubitemid 40013573)
48. Fishman A, Lorberboum-Galski H. Targeted elimination of cells expressing the high-affinity receptor for IgE (Fc epsilon RI) by a Pseudomonas exotoxin-based chimeric protein. Eur J Immunol 1997;27(2):486-94 (Pubitemid 27085254)
49. Fishman A, Prus D, Belostotsky R, et al. Targeted Fc2-3-PE40 chimeric protein abolishes passive cutaneous anaphylaxis in mice. Clin Exp Immunol 2000;119(3):398-403 (Pubitemid 30146333)
50. Brenner T, Steinberger I, Soffer D, et al. A novel antigen-toxin chimeric protein: myelin basic protein-pseudomonas exotoxin (MBP-PE 40) for treatment of experimental autoimmune encephalomyelitis. Immunol Lett 1999;68(2-3):403-10 (Pubitemid 29301906)
51. Bolognesi A, Polito L, Tazzari PL, et al. In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins. Br J Haematol 2000;110(2):351-61 (Pubitemid 30646861)
52. Endo Y, Mitsui K, Motizuki M, et al. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J Biol Chem 1987;262(12):5908-12
53. Zamboni M, Brigotti M, Rambelli F, et al. High-pressure- liquidchromatographic and fluorimetric methods for the determination of adenine released from ribosomes by ricin and gelonin. Biochem J 1989;259(3):639-43 (Pubitemid 19118827)
54. Mohanraj D, Ramakrishnan S. Cytotoxic effects of ricin without an interchain disulfide bond: genetic modification and chemical crosslinking studies. Biochim Biophys Acta 1995;1243(3):399-406
55. Ramakrishnan S, Bjorn MJ, Houston LL. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds. Cancer Res 1989;49(3):613-17 (Pubitemid 19050324)
56. Cook JP, Savage PM, Lord JM, et al. Biologically active interleukin 2-ricin A chain fusion proteins may require intracellular proteolytic cleavage to exhibit a cytotoxic effect. Bioconjug Chem 1993;4(6):440-7 (Pubitemid 2018179)
57. Dore JM, Gras E, Wijdenes J. Expression and activity of a recombinant chimeric protein composed of pokeweed antiviral protein and of human interleukin-2. FEBS Lett 1997;402(1):50-2 (Pubitemid 27056023)
58. Francisco JA, Gawlak SL, Siegall CB. Construction, expression, and characterization of BD1-G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin 1. J Biol Chem 1997;272(39):24165-9 (Pubitemid 27418614)
59. Cao Y, Marks JD, Marks JW, et al. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Res 2009;69(23):8987-95
60. Cizeau J, Grenkow DM, Brown JG, et al. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. J Immunother 2009;32(6):574-84
61. Kreitman RJ. Getting plant toxins to fuse. Leuk Res 1997;21(10):997-9 (Pubitemid 27511407)
62. Carroll SF, Collier RJ. Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin. J Biol Chem 1987;262(18):8707-11
63. Uchida T, Pappenheimer AM Jr, Harper AA. Reconstitution of diphtheria toxin from two nontoxic cross-reacting mutant proteins. Science 1972;175(24):901-3
64. Uchida T, Pappenheimer AM Jr, Greany R. Diphtheria toxin and related proteins. I. Isolation and properties of mutant proteins serologically related to diphtheria toxin. J Biol Chem 1973;248(11):3838-44
65. Iglewski BH, Liu PV, Kabat D. Mechanism of action of Pseudomonas aeruginosa exotoxin Aiadenosine diphosphate-ribosylation of mammalian elongation factor 2 in vitro and in vivo. Infect Immun 1977;15(1):138-44 (Pubitemid 8022697)
66. Van Ness BG, Howard JB, Bodley JW. ADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis products. J Biol Chem 1980;255(22):10717-20
67. Phan LD, Perentesis JP, Bodley JW. Saccharomyces cerevisiae elongation factor 2. Mutagenesis of the histidine precursor of diphthamide yields a functional protein that is resistant to diphtheria toxin. J Biol Chem 1993;268(12):8665-8 (Pubitemid 23118651)
68. Kreitman RJ, Batra JK, Seetharam S, et al. Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds. Bioconjug Chem 1993;4(2):112-20
69. Williams DP, Snider CE, Strom TB, et al. Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem 1990;265(20):11885-9
70. Chaudhary VK, FitzGerald DJ, Pastan I. A proper amino terminus of diphtheria toxin is important for cytotoxicity. Biochem Biophys Res Commun 1991;180(2):545-51
71. Kreitman RJ. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 2009;23(1):1-13
72. Frankel AE. Reducing the immune response to immunotoxin. Clin Cancer Res 2004;10(1 Pt 1):13-15 (Pubitemid 38114155)
73. Wang H, Song S, Kou G, et al. Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome. Cancer Immunol Immunother 2007;56(11):1775-83 (Pubitemid 47313082)
74. Hall PD, Virella G, Willoughby T, et al. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia. Clin Immunol 2001;100(2):191-7
75. Hertler AA, Spitler LE, Frankel AE. Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma. Cancer Drug Deliv 1987;4(4):245-53
76. Tsutsumi Y, Onda M, Nagata S, et al. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci USA 2000;97(15):8548-53 (Pubitemid 30639710)
77. Hansen JK, Weldon JE, Xiang L, et al. A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice. J Immunother 2010;33(3):297-304
78. Chen SY, Zani C, Khouri Y, et al. Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gene Ther 1995;2(2):116-23
79. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005;4(2):139-63 (Pubitemid 41351311)
80. Chipuk JE, Moldoveanu T, Llambi F, et al. The BCL-2 family reunion. Mol Cell 2010;37(3):299-310
81. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9(1):47-59
82. Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010;11(9):621-32
83. Ow YP, Green DR, Hao Z, et al. Cytochrome c: functions beyond respiration. Nat Rev Mol Cell Biol 2008;9(7):532-42 (Pubitemid 351881842)
84. Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol 2005;5(3):189-200 (Pubitemid 40364821)
85. Aqeilan R, Kedar R, Ben-Yehudah A, et al. Mechanism of action of interleukin-2 (IL-2)-Bax, an apoptosis-inducing chimaeric protein targeted against cells expressing the IL-2 receptor. Biochem J 2003;370(Pt 1):129-40 (Pubitemid 36262022)
86. Lorberboum-Galski H, Barrett LV, Kirkman RL, et al. Cardiac allograft survival in mice treated with IL-2-PE40. Proc Natl Acad Sci USA 1989;86(3):1008-12 (Pubitemid 19056279)
87. Lorberboum-Galski H, FitzGerald D, Chaudhary V, et al. Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli. Proc Natl Acad Sci USA 1988;85(6):1922-6 (Pubitemid 24315796)
88. Lorberboum-Galski H, Garsia RJ, Gately M, et al. IL2-PE664Glu, a new chimeric protein cytotoxic to human-activated T lymphocytes. J Biol Chem 1990;265(27):16311-17
89. Lorberboum-Galski H, Kozak RW, Waldmann TA, et al. Interleukin 2 (IL2) PE40 is cytotoxic to cells displaying either the p55 or p70 subunit of the IL2 receptor. J Biol Chem 1988;263(35):18650-6 (Pubitemid 19016324)
90. Lorberboum-Galski H, Lafyatis R, Case JP, et al. Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion. Int J Immunopharmacol 1991;13(2-3):305-15
91. Kozak RW, Lorberboum-Galski H, Jones L, et al. IL-2-PE40 prevents the development of tumors in mice injected with IL-2 receptor expressing EL4 transfectant tumor cells. J Immunol 1990;145(8):2766-71 (Pubitemid 20374609)
92. Beraud E, Lorberboum-Galski H, Chan CC, et al. Immunospecific suppression of encephalitogenic-activated T lymphocytes by chimeric cytotoxin IL-2-PE40. Cell Immunol 1991;133(2):379-89
93. BenEzra D, Maftzir G, Hochberg E, et al. Ocular distribution of the chimeric protein IL2-PE40. Curr Eye Res 1995;14(2):153-8
94. Herbort CP, de Smet MD, Roberge FG, et al. Treatment of corneal allograft rejection with the cytotoxin IL-2-PE40. Transplantation 1991;52(3):470-4
95. Ogata M, Lorberboum-Galski H, FitzGerald D, et al. IL-2-PE40 is cytotoxic for activated T lymphocytes expressing IL-2 receptors. J Immunol 1988;141(12):4224-8 (Pubitemid 19018209)
96. Roberge FG, Lorberboum-Galski H, Le Hoang P, et al. Selective immunosuppression of activated T cells with the chimeric toxin IL-2-PE40. Inhibition of experimental autoimmune uveoretinitis. J Immunol 1989;143(11):3498-502 (Pubitemid 20007011)
97. Steinberger I, Ben-Bassat H, Hochberg E, et al. Interleukin-2 (IL-2) receptor alpha, beta and gamma subunit expression as a function of B-cell lineage ontogeny: the use of IL-2-PE66(4Glu) to characterize internalization via IL-2 receptor subunits. Scand J Immunol 1997;46(2):129-36 (Pubitemid 27323840)
98. Steinberger I, Brenner T, Lorberboum-Galski H. Interleukin-2 Pseudomonas exotoxin chimeric protein is cytotoxic to B cell cultures derived from myasthenia gravis patients. J Neurol Sci 1995;133(1-2):183-91
99. Steinberger I, Brenner T, Lorberboum-Galski H. Interleukin 2 pseudomonas exotoxin (IL2-PE66(4) Glu) chimeric protein kills B cells from patients with Myasthenia gravis. Cell Immunol 1996;169(1):55-61
100. Aqeilan R, Yarkoni S, Lorberboum-Galski H. Interleukin 2-Bax: a novel prototype of human chimeric proteins for targeted therapy. FEBS Lett 1999;457(2):271-6 (Pubitemid 29401941)
101. Azar Y, Lorberboum-Galski H. GnRH-Bik/Bax/Bak chimeric proteins target and kill adenocarcinoma cells; the general use of pro-apoptotic proteins of the Bcl-2 family as novel killing components of targeting chimeric proteins. Apoptosis 2000;5(6):531-42 (Pubitemid 32182551)
102. Belostotsky R, Lorberboum-Galski H. Apoptosis-inducing human-origin Fcepsilon-Bak chimeric proteins for targeted elimination of mast cells and basophils: a new approach for allergy treatment. J Immunol 2001;167(8):4719-28 (Pubitemid 32954354)
103. Luo X, Budihardjo I, Zou H, et al. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94(4):481-90 (Pubitemid 28391864)
104. Wang K, Yin XM, Chao DT, et al. BID: a novel BH3 domain-only death agonist. Genes Dev 1996;10(22):2859-69 (Pubitemid 26394246)
105. Li H, Zhu H, Xu CJ, et al. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94(4):491-501 (Pubitemid 28391865)
106. Yin XM. Signal transduction mediated by Bid, a pro-death Bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathways. Cell Res 2000;10(3):161-7
107. Shan LQ, Qiu XC, Xu YM, et al. scFv-mediated delivery of truncated BID suppresses HER2-positive osteosarcoma growth and metastasis. Cancer Biol Ther 2008;7(11):1717-22
108. Wang F, Ren J, Qiu XC, et al. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence. Clin Cancer Res 2010;16(8):2284-94
109. Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene 2008;27(48):6194-206
110. Jia LT, Zhang LH, Yu CJ, et al. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3. Cancer Res 2003;63(12):3257-62
111. Zhang DX, Zhao PT, Xia L, et al. Potent inhibition of human gastric cancer by HER2-directed induction of apoptosis with anti-HER2 antibody and caspase-3 fusion protein. Gut 2010;59(3):292-9
112. Wang LF, Zhou Y, Xu YM, et al. A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma. Cancer Invest 2009 27(7):774-80
113. Shteingart S, Rapoport M, Grodzovski I, et al. Therapeutic potency of IL2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease. Gut 2009;58(6):790-8
114. Sagiv Y, Kaminitz A, Lorberboum-Galski H, et al. A fusion protein composed of IL-2 and caspase-3 ameliorates the outcome of experimental inflammatory colitis. Ann NY Acad Sci 2009 1173:791-7
115. Irony-Tur-Sinai M, Lichtenstein M, Brenner T, et al. IL2-caspase3 chimeric protein controls lymphocyte reactivity by targeted apoptosis, leading to amelioration of experimental autoimmune encephalomyelitis. Int Immunopharmacol 2009;9(10):1236-43
116. Kurschus FC, Jenne DE. Delivery and therapeutic potential of human granzyme B. Immunol Rev 2010 235(1):159-71
117. Rosenblum MG, Barth S. Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions. Curr Pharm Des 2009;15(23):2676-92
118. Kurschus FC, Fellows E, Stegmann E, et al. Granzyme B delivery via perforin is restricted by size, but not by heparan sulfate-dependent endocytosis. Proc Natl Acad Sci USA 2008 105(37):13799-804
119. Froelich CJ, Orth K, Turbov J, et al. New paradigm for lymphocyte granule-mediated cytotoxicity. Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and subsequent apoptosis. J Biol Chem 1996 271(46):29073-9 (Pubitemid 26382614)
120. Bird CH, Sun J, Ung K, et al. Cationic sites on granzyme B contribute to cytotoxicity by promoting its uptake into target cells. Mol Cell Biol 2005 25(17):7854-67 (Pubitemid 41170144)
121. Shi L, Keefe D, Durand E, et al. Granzyme B binds to target cells mostly by charge and must be added at the same time as perforin to trigger apoptosis. J Immunol 2005 174(9):5456-61 (Pubitemid 40593185)
122. Bots M, Medema JP. Granzymes at a glance. J Cell Sci 2006 119(Pt 24):5011-4 (Pubitemid 46085180)
123. Lieberman J. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol 2003 3(5):361-70 (Pubitemid 37323196)
124. Grodzovski I, Lichtenstein M, Galski H, et al. IL-2-granzyme A chimeric protein overcomes multidrug resistance (MDR) through a caspase 3-independent apoptotic pathway. Int J Cancer 2011;128(8):1966-80
125. Enari M, Sakahira H, Yokoyama H, et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998 391(6662):43-50 (Pubitemid 28079208)
126. Halenbeck R, MacDonald H, Roulston A, et al. CPAN, a human nuclease regulated by the caspase-sensitive inhibitor DFF45. Curr Biol 1998 8(9):537-40 (Pubitemid 28203075)
127. Mukae N, Enari M, Sakahira H, et al. Molecular cloning and characterization of human caspase-activated DNase. Proc Natl Acad Sci USA 1998 95(16):9123-8 (Pubitemid 28506195)
128. Nagata S. Apoptotic DNA fragmentation. Exp Cell Res 2000 256(1):12-8 (Pubitemid 30211161)
129. Ben-Yehudah A, Aqeilan R, Robashkevich D, et al. Using apoptosis for targeted cancer therapy by a new gonadotropin releasing hormone-DNA fragmentation factor 40 chimeric protein. Clin Cancer Res 2003 9(3):1179-90 (Pubitemid 36323728)
130. Mahmud H, Dalken B, Wels WS. Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor. Mol Cancer Ther 2009 8(6):1526-35
131. Cleveland JL, Ihle JN. Contenders in FasL/TNF death signaling. Cell 1995 81(4):479-82
132. Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996 271(22):12687-90 (Pubitemid 26175834)
133. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003 10(1):66-75 (Pubitemid 36511833)
134. Kischkel FC, Lawrence DA, Chuntharapai A, et al. Apo2L/TRAILdependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000 12(6):611-20
135. Sprick MR, Weigand MA, Rieser E, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000 12(6):599-609
136. Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997 277(5327):815-18 (Pubitemid 27366732)
137. Carlo-Stella C, Lavazza C, Locatelli A, et al. Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res 2007 13(8):2313-17 (Pubitemid 46698578)
138. Bremer E, Kuijlen J, Samplonius D, et al. Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer 2004 109(2):281-90 (Pubitemid 38240933)
139. Bremer E, Samplonius DF, Peipp M, et al. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res 2005 65(8):3380-8 (Pubitemid 40524623)
140. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993 364(6440):806-9 (Pubitemid 23261761)
141. Rensing-Ehl A, Frei K, Flury R, et al. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 1995 25(8):2253-8
142. Schneider P, Holler N, Bodmer JL, et al. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998;187(8):1205-13 (Pubitemid 28189110)
143. Bremer E, ten Cate B, Samplonius DF, et al. CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. Blood 2006 107(7):2863-70
144. Zewe M, Rybak SM, Dubel S, et al. Cloning and cytotoxicity of a human pancreatic RNase immunofusion. Immunotechnology 1997 3(2):127-36 (Pubitemid 27356791)
145. Psarras K, Ueda M, Yamamura T, et al. Human pancreatic RNase1-human epidermal growth factor fusion: an entirely human immunotoxin analog with cytotoxic properties against squamous cell carcinomas. Protein Eng 1998 11(12):1285-92 (Pubitemid 29012140)
146. Futami J, Seno M, Ueda M, et al. Inhibition of cell growth by a fused protein of human ribonuclease 1 and human basic fibroblast growth factor. Protein Eng 1999 12(11):1013-19
147. Psarras K, Ueda M, Tanabe M, et al. Targeting activated lymphocytes with an entirely human immunotoxin analogue: human pancreatic RNase1-human IL-2 fusion. Cytokine 2000 12(6):786-90 (Pubitemid 30453518)
148. De Lorenzo C, Nigro A, Piccoli R, et al. A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells. FEBS Lett 2002 516(1-3):208-12 (Pubitemid 34311963)
149. Newton DL, Nicholls PJ, Rybak SM, et al. Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophil-derived neurotoxin-anti-transferrin receptor sFv. J Biol Chem 1994 269(43):26739-45 (Pubitemid 24332866)
150. Yoon JM, Han SH, Kown OB, et al. Cloning and cytotoxicity of fusion proteins of EGF and angiogenin. Life Sci 1999;64(16):1435-45 (Pubitemid 29185272)
151. Newton DL, Pollock D, DiTullio P, et al. Antitransferrin receptor antibody-RNase fusion protein expressed in the mammary gland of transgenic mice. J Immunol Methods 1999 231(1-2):159-67 (Pubitemid 30394731)
152. Huhn M, Sasse S, Tur MK, et al. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res 2001 61(24):8737-42 (Pubitemid 34013885)
153. Tur MK, Neef I, Jager G, et al. Immunokinases, a novel class of immunotherapeutics for targeted cancer therapy. Curr Pharm Des
154. Tur MK, Neef I, Jost E, et al. Targeted restoration of down-regulated DAPK2 tumor suppressor activity induces apoptosis in Hodgkin lymphoma cells. J Immunother 2009 32(5):431-41